Rattlesnake Bite Shocks Family With $300k Bill

A family in San Diego was charged $297,461 in medical bills after their two-year-old boy, Brigland Pfeffer, was bitten by a rattlesnake in his backyard

The poison moved quickly through Brigland’s body. By the time they reached the hospital, the toddler’s hand was swollen and purple.

Unable to start an IV (intravenous therapy), the medical staff administered the antivenom using a procedure called intraosseous vascular access, which delivers medicine into the bone marrow cavity.

The boy was then transferred to the pediatric intensive care unit at Rady Children’s Hospital, the largest children’s hospital on the West Coast, where he received more antivenom. In the end, it took 30 vials of antivenom to treat him.

“Nobody understands how he’s alive. This is unheard of why he actually made it,” Pfeffer said. “Because he’s 2, he’s more likely to die, but because he’s 2, he’s more likely to heal. But you have to survive to get there.”

The Pfeffers were charged a total of $297,461 for the treatment, which included two ambulance rides, an emergency room visit, and a couple of days in pediatric intensive care, according to KFF Health News.

Anavip, the antivenom used on the boy, accounts for $213,278.80 of the bill.

Lindsay Pfeffer, the boy’s mom, called 911 immediately after he heard his son scream and saw a rattlesnake, the largest venomous snake in the US

Brigland’s family was charged two different prices for Anavip at the healthcare facilities.

Palomar Medical Center—the first hospital the boy visited—charged $9,574.60 per vial, for a total of $95,746 for the first 10 doses of the antivenom. 

Then, Rady Children’s Hospital charged $5,876.64 for each vial, totaling $117,532.80 for the 20 vials Brigland received there.

Medicare—the US government program for those with limited income and resources—pays about $2,000 for a vial of Anavip, which is the price hospitals pay for the antivenom, according to Stacie Dusetzina, a professor of health policy at Vanderbilt University Medical Center.

“Nobody understands how he’s alive. This is unheard of why he actually made it,” Lindsay said

Leslie Boyer, a doctor and toxicology researcher, broke down the cost of antivenom in a 2015 editorial published in the American Journal of Medicine.

Boyer’s study reveals that the hefty price of antivenom in the US is not due to high manufacturing costs or the cost of the drug itself; instead, it appears to be the result of hospitals marking the product up to cover operational expenses and increase profits.

Gathering data from factory supervisors, animal managers, hospital pharmacists, and other sources, the doctor estimated the cost of a hypothetical antivenom at $14,624 per vial. (On average, a patient requires 18 vials to treat a snakebite, as per KFF Health News.)

Where does this figure come from? According to Boyer, the venom itself accounts for only 2 cents of the total. Manufacturing costs $9, and clinical trials account for $300 per vial.

But $10,250—over 70% of the total price—is attributable to hospital charges.

“By far the greatest contributor to final patient billing was the portion of hospital charges later discounted for contracted payers, a negotiated amount that varied widely among hospitals but that does not represent actual collections for the majority of patients,” the doctor wrote.

“This analysis demonstrates that well more than half of the astonishing hospital charges reported in the lay media are not true costs at all, but are instead attributable to the idiosyncrasies of the US healthcare finance system.”

Moreover, there are only two big manufacturers in the antivenom market (Anavip and CroFab), which also explains the sky-high cost of the drug. In the US, even when the FDA approves a cheaper copycat drug, manufacturers can manipulate the patent process to keep competitors out by claiming ownership of certain product information, as per KFF Health News.

When Anavip entered the market, they were sued for patent infringement by CroFab’s maker. The case was settled in 2014, with Anavip promising to pay BTG royalties on its sales of antivenom until 2028. As a result, the manufacturer raised their prices to cover the millions of dollars in legal costs, Boyer said.

Anavip, the antivenom used on the boy, accounts for $213,278.80 of the total medical bill

Robin Feldman, a professor at UC Hastings College of the Law in San Francisco who specializes in pharmacy law, explained that the American drug pricing system is governed by “perverse incentives.”

“When a child is bitten by a snake, the family shouldn’t be bitten again by the healthcare system,” the author of  Drugs, Money, & Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices told Bored Panda via email.

“All the parties benefit when the price rises. Hospitals and private insurance plans can mark up the prices to cover their many costs; middle players—who should be negotiating for lower prices—actually pocket more when the prices rise; and, of course, pharmaceutical companies make more when they can raise the prices, even after accounting for what the other players take out of the system.

“Patents and non-patent exclusivities (such as Orphan Drug Designation) help pharmaceutical companies extend protection of their drugs, a practice some call ‘life-cycle management’ and others call ‘evergreening.'”

Pharmaceutical companies may offer coupon programs for those who can’t afford a certain drug. However, Feldman points out that this is not a solution for emergency medications, as patients need treatment immediately.

“Companies can try to bargain with the hospital. Often, the hospital or others will negotiate. But families should beware. Aggressive hospitals or billers can dispatch aggressive debt collection agencies that can hound the family and ruin their credit.”

Some facilities provide care even if patients don’t have insurance, added Dr. Kenneth H. Schell, a pharmacy regulatory and compliance consultant and professor of Pharmacy Law and Ethics. In these cases, the cost is arranged between the healthcare facility and the patient.

“There are manufacturer programs and other methods to help the patient pay. In addition, if the patient meets certain criteria, State Medicaid programs can be employed,” Dr. Schell told Bored Panda.